Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 11.21% is 54% below its 5-year average of 24.24%, near the low end of its 5-year range (11.21%–54.38%).
As of the fiscal period ended Tuesday, June 30, 2026. 26.22% below its 12-month average of 15.20%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 11.21%.
DEBT TO ASSETS RATIO
11.21%
DEBT TO ASSETS RATIO AVG TTM
15.20%
DEBT TO ASSETS RATIO AVG 3Y
19.31%
DEBT TO ASSETS RATIO AVG 5Y
24.24%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-26.22%
CURRENT VS 3Y AVG
-41.94%
CURRENT VS 5Y AVG
-53.74%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 584 covered companies
CURRENT VS SECTOR MEDIAN
+11112.79%
vs the sector median at left
Harmony Biosciences Holdings, Inc.
Market Cap
$2.27B
Debt to Assets Ratio
11.21%
TTM Avg
15.20%
3Y Avg
19.31%
5Y Avg
24.24%
Market Cap
$2.28B
Debt to Assets Ratio
0.29%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.32B
Debt to Assets Ratio
0.30%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.33B
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.38B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.40B
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.11B
Debt to Assets Ratio
0.41%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.10B
Debt to Assets Ratio
0.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | $2.27B | 11.21% | 15.20% | 19.31% | 24.24% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.28B | 0.29% | N/A | N/A | N/A |
| ADMA Biologics, Inc. (ADMA)vs › | $2.32B | 0.30% | N/A | N/A | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.33B | 0.05% | N/A | N/A | N/A |
| Clover Health Investments, Corp. (CLOV)vs › | $2.38B | 0.00% | N/A | N/A | N/A |
| Liquidia Corporation (LQDA)vs › | $2.40B | 0.25% | N/A | N/A | N/A |
| Disc Medicine, Inc. (IRON)vs › | $2.40B | 0.08% | N/A | N/A | N/A |
| Fortrea Holdings Inc. (FTRE)vs › | $2.11B | 0.41% | N/A | N/A | N/A |
| Addus HomeCare Corporation (ADUS)vs › | $2.10B | 0.07% | N/A | N/A | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.09B | 0.01% | N/A | N/A | N/A |
Debt/Assets
11.2%
Debt/Equity
0.15
Current Ratio
3.48
Interest Coverage
14.2x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 11.21% |
| 2026-03-31 | 16.24% |
| 2025-12-31 | 18.84% |
| 2025-09-30 | 14.05% |
| 2025-06-30 | 15.65% |
| 2025-03-31 | 16.81% |
| 2024-12-31 | 18.16% |
| 2024-09-30 | 19.96% |
| 2024-06-30 | 22.03% |
| 2024-03-31 | 22.79% |
| 2023-12-31 | 24.16% |
| 2023-09-30 | 25.68% |
| 2023-06-30 | 25.48% |
| 2023-03-31 | 26.79% |
| 2022-12-31 | 28.44% |
| 2022-09-30 | 29.80% |
| 2022-06-30 | 37.98% |
| 2022-03-31 | 41.36% |
| 2021-12-31 | 45.16% |
| 2021-09-30 | 49.11% |
| 2021-06-30 | 54.38% |
| 2021-03-31 | 57.79% |
| 2020-12-31 | 45.48% |
| 2020-09-30 | 60.25% |
| 2020-06-30 | 114.04% |
| 2020-03-31 | 117.83% |
| 2019-12-31 | 91.79% |
